Amazon Stock Rebounds After Earnings as $200B Capex Plan Sparks AI Spending Debate 
DBS Expects Slight Dip in 2026 Net Profit After Q4 Earnings Miss on Lower Interest Margins 
Weight-Loss Drug Ads Take Over the Super Bowl as Pharma Embraces Direct-to-Consumer Marketing 
Samsung Electronics Shares Jump on HBM4 Mass Production Report 
Washington Post Publisher Will Lewis Steps Down After Layoffs 
Kroger Set to Name Former Walmart Executive Greg Foran as Next CEO 
Trump Administration Plans Chip Tariff Exemptions for Big Tech Amid AI Data Center Push 
Canadian Airlines Suspend Cuba Flights Amid Jet Fuel Shortage and U.S. Sanctions 
American Airlines CEO to Meet Pilots Union Amid Storm Response and Financial Concerns 
Innovent Biologics Shares Rally on New Eli Lilly Oncology and Immunology Deal 
Alphabet Plans Rare 100-Year Sterling Bond to Fund AI Expansion 
Anta Sports Expands Global Footprint With Strategic Puma Stake 
Toyota’s Surprise CEO Change Signals Strategic Shift Amid Global Auto Turmoil 
American Airlines CEO to Meet Pilots Union Amid Storm Response and Financial Concerns 
SpaceX Pivots Toward Moon City as Musk Reframes Long-Term Space Vision 
FDA Targets Hims & Hers Over $49 Weight-Loss Pill, Raising Legal and Safety Concerns 
Nvidia CEO Jensen Huang Says AI Investment Boom Is Just Beginning as NVDA Shares Surge 
NEW YORK, Nov. 16, 2017 -- The Law Offices of Vincent Wong announce that a class action lawsuit has been commenced in the U.S. District Court for the District of Massachusetts on behalf of investors who purchased Genocea Biosciences, Inc. ("Genocea Biosciences") (NASDAQ:GNCA) securities between May 5, 2017 and September 25, 2017.
Click here to learn about the case: http://www.wongesq.com/pslra-sb/genocea-biosciences-inc?wire=3. There is no cost or obligation to you.
According to the complaint, throughout the Class Period, the Company issued materially false and misleading statements and/or failed to disclose that: (i) the Company's finances were insufficient to support Phase 3 trials of GEN-003; (ii) accordingly, Genocea had overstated the prospects for GEN-003; and (iii) as a result of the foregoing, Genocea's public statements were materially false and misleading at all relevant times.
On September 25, 2017, Genocea disclosed that it was halting spending and activities on GEN-003 and exploring strategic alternatives for the drug. The Company also announced that it was cutting 40% of its workforce.
If you suffered a loss in Genocea Biosciences you have until January 2, 2018 to request that the Court appoint you as lead plaintiff. Your ability to share in any recovery doesn’t require that you serve as a lead plaintiff. To obtain additional information, contact Vincent Wong, Esq. either via email [email protected], by telephone at 212.425.1140, or visit http://www.wongesq.com/pslra-sb/genocea-biosciences-inc?wire=3 .
Vincent Wong, Esq. is an experienced attorney that has represented investors in securities litigations involving financial fraud and violations of shareholder rights. Attorney advertising. Prior results do not guarantee similar outcomes.
CONTACT:
Vincent Wong, Esq.
39 East Broadway
Suite 304
New York, NY 10002
Tel. 212.425.1140
Fax. 866.699.3880
E-Mail: [email protected]
